We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The FDA's rejection of the marketing of SYD985 is just the beginning, and with the rising enthusiasm for the R&D of ADCs, the standards of subsequent review by the FDA of the popular target ADCs will be inevitably raised.